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SUMMARY – Stroke is a rapidly developing clinical disturbance of focal or global cerebral 
function, lasting for more than 1 hour. It is an acute form of symptoms of brain function disorder, 
with no apparent cause other than vascular origin. It is the final phase of arterial disease, the main 
cause of disability, and the second leading cause of death. Today, ischemic stroke can be treated su-
ccessfully by acting on its cause using a very powerful weapon, thrombolytic therapy. The aim is to 
present a preliminary report of our experiences with thrombolytic therapy in patients with ischemic 
stroke. Results recorded in 20 patients who received thrombolytic therapy within three hours of 
stroke onset are presented. Nineteen patients survived and one patient died from therapy side effects, 
i.e. intracerebral hematoma. Seventeen of 19 patients were released from the hospital without any 
neurologic deficit, while two patients had Rankin score 2 (minimum disability) three months after 
stroke onset. Our experience confirms that thrombolytic therapy is the treatment of choice in pati-
ents with ischemic stroke if administered in accordance with precise protocols.
Key words: Stroke; Brain ischemia; Thrombolytic therapy 
Correspondence to: Siniša Miljković, MD, PhD, University De-
partment of Neurology, Banjaluka Clinical Center, 12 Beba bb, 
Banjaluka, Republika Srpska, Bosnia and Herzegovina
E-mail: neurologija@blic.net
Received May 27, 2009, accepted July 25, 2011 
Introduction
Cerebrovascular diseases are a serious health prob-
lem, increasingly common worldwide, causing severe 
disabilities and creating an enormous burden on the 
social and health care systems. Stroke is the second 
leading cause of death, responsible for 4.4 million 
(9%) of the total 50.5 million deaths each year, and 
it is the leading cause of adult disability. Globally, 
stroke death rates vary widely; the highest rates are in 
Portugal, China, Korea, and most of Eastern Europe, 
and the lowest rates are in Switzerland, Canada, and 
the United States. Acute ischemic stroke accounts for 
approximately 80% of all strokes, and occurs when a 
thrombus, or embolism, blocks a cerebral blood ves-
sel. Resulting mortality and morbidity, particularly 
long-term disability, are high. Approximately 20% of 
patients will die within thirty days of stroke onset, 
and many are left permanently disabled1.
In 70%-80% of cases, stroke is caused by brain 
infarctions. An ischemic type of cerebrovascular dis-
ease, simply called ischemic stroke, is more frequent 
than hemorrhagic stroke. In the European popula-
tion, ischemic stroke accounts for up to 80% of all 
cerebrovascular events, is frequent in middle-aged 
and older individuals, and often leads to prolonged 
hospitalization, disability, or death. It is likely that 
the progressive aging of Western populations will 
raise the number of ischemic stroke events in the fu-
ture. Therefore, the prevention and better treatment 
of ischemic stroke has considerable public health sig-
nificance. The 3-month mortality rate from ischemic 
stroke is approximately 12%. However, patients who 
are candidates for thrombolytic stroke therapy tend 
to have more severe strokes than the average patient 
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with ischemic stroke. The 3-month mortality rate in 
these more severe patients is approximately 21% when 
they do not receive thrombolytic therapy. This death 
rate is not increased by the use of thrombolytic treat-
ment. Common acute complications of stroke include 
pneumonia, urinary tract infection, and pulmonary 
embolism. Long-term morbidity in survivors of stroke 
is common, with ambulation difficulty in 20%, need 
for assistance in activities of daily living in 30%, and 
vocational disability in 50%-70% of patients. Com-
parison of stroke rates among races is confounded by 
socioeconomic, environmental, and nutritional fac-
tors. The age-adjusted incidence rate for black men 
is 1.5 times higher than that for white men; that for 
black women is 2.3 times higher than that for white 
women. The male-to-female ratio for stroke is about 
1.35:1. The incidence of stroke doubles in every de-
cade after age 45, rising from 104 per 100,000 per year 
for adults aged 45-54 to 111.3 per 100,000 per year 
for adults aged 75-84. Two thirds of strokes occur in 
persons older than 652-5.
The most common risk factors for ischemic stroke 
are age, hypertension, diabetes, smoking, atrial fi-
brillation, hypercholesterolemia, and coronary artery 
disease. Mechanisms of ischemic stroke are in situ 
atherothrombosis, artery to artery embolism, car-
dioembolism, lipohyalinosis, and hypercoagulable 
state6.
The thrombolytic agent, recombinant tissue plas-
minogen activator (rt-PA/alteplase) has been approved 
for the treatment of acute ischemic stroke within three 
hours of symptom onset. It is the first thrombolytic 
agent to be licensed for this indication and has the 
potential to radically change the early management of 
acute ischemic stroke and reduce resultant disability. 
Recommendations for Thrombolysis 
Intravenous rtPA (0.9 mg/kg body weight, maxi-
mum 90 mg), with 10% of the dose given as a bolus 
followed by a 60-minute infusion, is recommended 
within 4.5 hours of the onset of ischemic stroke (Class 
I, Level A), although treatment between 3 and 4.5 h is 
currently not included in the European labeling.
− Second bullet point removed
−  Further bullet points unchanged
•	 The	 use	 of	 multimodal	 imaging	 criteria	 may	 be	
useful in patient selection for thrombolysis but 
is not recommended for routine clinical practice 
(Class III, Level C)
•	 It	is	recommended	that	blood	pressures	of	185/110	
mm Hg or higher is lowered before thrombolysis 
(Class IV, GCP)
•	 It	is	recommended	that	intravenous	rtPA	may	be	
used in patients with seizures at stroke onset, if 
the neurologic deficit is related to acute cerebral 
ischemia (Class IV, GCP)
•	 It	is	recommended	that	intravenous	rtPA	may	also	
be administered in selected patients under 18 and 
over 80 years of age, although this is outside the 
current European labeling (Class III, Level C)
•	 Intra-arterial	 treatment	 of	 acute	MCA	occlusion	
within a 6-hour time window is recommended as 
an option (Class II, Level B)
•	 Intra-arterial	 thrombolysis	 is	 recommended	 for	
acute basilar occlusion in selected patients (Class 
III, Level B). Intravenous thrombolysis for basilar 
occlusion is an acceptable alternative even after 3 
hours (Class III, Level B)
•	 It	is	recommended	that	aspirin	(160-325	mg	load-
ing dose) be given within 48 hours after ischemic 
stroke (Class I, Level A)
•	 It	is	recommended	that	if	thrombolytic	therapy	is	
planned or given, aspirin or other antithrombotic 
therapy should not be initiated within 24 hours 
(Class IV, GCP)
•	 The	use	of	other	antiplatelet	agents	(single	or	com-
bined) is not recommended in the setting of acute 
ischemic stroke (Class III, Level C)
•	 The	administration	of	glycoprotein IIb/IIIa inhibi-
tors is not recommended (Class I, Level A)
•	 Early	 administration	 of	 unfractionated	 heparin,	
low molecular weight heparin or heparinoids is not 
recommended for the treatment of patients with 
acute ischemic stroke (Class I, Level A)
•	 Currently,	 there	 is	 no	 recommendation	 to	 treat	
ischemic stroke patients with neuroprotective sub-
stances (Class I, Level A)
The recently published European Cooperative 
Acute Stroke Study III (ECASS III) has shown that 
intravenous alteplase administered between 3 and 4.5 
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hours (median 3 h 59 min) after the onset of symptoms 
significantly improves clinical outcomes in patients 
with acute ischemic stroke compared to placebo. The 
absolute improvement was 7.2% and the adjusted OR 
of favorable outcome (mRS 0-1) was 1.42, 1.02-1.98. 
Mortality did not differ significantly (7.7% vs. 8.4%), 
but alteplase increased the risk of symptomatic intrac-
erebral hemorrhage (sICH) (2.4% vs. 0.2%). Treat-
ment benefit is time-dependent. The number needed 
to treat to get one more favorable outcome drops from 
two during the first 90 minutes through seven within 
3 hours and towards 14 between 3 and 4.5 hours7.
The SITS investigators compared 664 patients 
with ischemic stroke treated between 3 and 4.5 hours, 
otherwise compliant with the European summary of 
the product characteristics criteria, with 11,865 pa-
tients treated within 3 hours8.
In the 3-4.5 hour cohort, treatment was started on 
an average 55 minutes after the stroke onset. There 
were no significant differences between the 3-4.5 
hour cohort and the 3-hour cohort for any outcome 
measures, confirming that alteplase remains safe 
when given between 3 and 4.5 hours after the onset of 
symptoms in ischemic stroke patients who otherwise 
fulfill the European summary of product characteris-
tics criteria9.
Materials and Methods
This preliminary report presents our experience 
with the first 20 patients who received thrombolytic 
therapy within the three-hour period following stroke 
onset at the Stroke Unit in Banjaluka, the first stroke 
unit in Bosnia and Herzegovina. We made our proto-
col for thrombolytic therapy according to the experi-
ence of our colleagues from Serbia.
Inclusion criteria are as follows: treatment must 
be initiated within 3 hours of symptom onset; to be 
considered for thrombolytic therapy, the patient must 
have more than a minimal neurologic deficit; neuro-
logic deficit must be stable; patients with the National 
Institutes of Health Stroke Scale (NIHSS) score 4-22 
are candidates for this treatment.
Exclusion criteria are: rapidly improving neuro-
logic signs; systolic blood pressure (SBP) above 185 
mm Hg or diastolic blood pressure (DBP) above 110 
mm Hg; seizure at stroke onset; symptoms suggestive 
of subarachnoid hemorrhage; stroke or serious head 
trauma within previous 3 months; major surgery or 
serious bodily trauma within previous 2 weeks; his-
tory of ICH; intracranial neoplasm; arteriovenous 
malformation or aneurysm; gastrointestinal or uri-
nary tract hemorrhage within 21 days; arterial punc-
ture at a noncompressible site or lumbar puncture 
within 1 week; concomitant oral anticoagulant (INR 
>1.7); platelet count <100x109/L; prothrombin time 
(PT) >15 (INR >1.7); activated partial thromboplas-
tin time (aPTT) elevated beyond reference range; 
glucose range between 2.7 and 22.2 mmol/L; and 
positive pregnancy test (in women of childbearing 
age).
Imaging studies: immediate head computed to-
mography (CT) scanning is an imperative. Any ICH 
is an absolute contraindication to thrombolysis; early 
signs of major infarction on initial CT scan are a rea-
son for caution in the use of thrombolytic therapy be-
cause the risk of hemorrhage is increased. 
Other tests: Transcranial Color Coded Duplex 
Sonography (TCCD); an electrocardiogram (ECG) 
is required before administering tPA. 
Medical care: stabilize airway, breathing, circula-
tion, and acute life-threatening conditions; identify 
time of and witnesses to stroke onset; place intrave-
nous line en route, if possible; arrange for emergency 
head CT and laboratory studies and TCCD; monitor 
BP at least every 15 minutes before tPA; monitor for 
improvement of neurologic deficits; place a Foley in-
dwelling catheter and nasogastric tube, if necessary, 
prior to starting tPA; during and after tPA infusion, 
monitor BP at least every 15 minutes for 2 hours; aim 
for a “door-to-needle time” (interval from patient ar-
rival at emergency department to start of thrombolytic 
therapy) of 60 minutes. 
Consultations: cardiologist and neuroradiologist.
Diet: nothing by mouth 24 hours after treatment.
Further inpatient care: no antiplatelet or antico-
agulant therapy should be administered for 24 hours 
following tPA; obtain a repeat head CT scan 24 hours 
after tPA to rule out asymptomatic hemorrhagic trans-
formation prior to initiating antithrombotic therapy; 
BP should be monitored closely and controlled (every 
1 hour for the next 6 hours after treatment); physical, 
occupational, and speech therapy is initiated after the 
first 24 hours of bed rest.
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Results
In the total number of patients (N=20) who re-
ceived thrombolytic therapy, there were 10 male and 
10 female patients. The youngest male patient was 40 
and the youngest female patient 35 years old, while 
the oldest male patient was 68 and the oldest female 
patient 74 years old. The mean age of male and female 
patients was 55.3 and 62.50 years, respectively. The 
mean time of receiving Actilyse was 117.4 minutes af-
ter the onset of symptoms. The NIHSS on admission 
ranged from 5 to 18 (mean, 12.9) in male and from 5 
to 17 (mean, 10.2) in female patients. In both male 
and female patients, the admission NIHSS was a pre-
dictor of poorer response to therapy received.
The NIHSS at discharge in male patients ranged 
from 0 to 11 (mean, 2.44). One patient who scored 11 
had not received tPA within the 3-hour therapeutic 
window, as we found out later. In female patients, the 
NIHSS at discharge ranged from 0 to 11 (mean, 1.4). 
Overall, female patients showed better therapeutic re-
sponse than male patients, although their NIHSSs on 
admission were lower. 
Rankin scores at discharge indicated that upon 
leaving the hospital, 13 patients were fully capable 
of self care and without any neurologic deficit, three 
patients had minimal deficit that completely resolved 
after three months, and one patient died within the 
first 24 hours following tPA. Out of 20 patients, 19 
survived and one patient died from therapy side effect, 
i.e. intracerebral hematoma. 
The most common risk factor in male patients was 
hyperlipidemia, followed by hypertension, smoking 
and diabetes, whereas in female patients the most 
common risk factors were hypertension, hyperlipi-
demia, smoking, obesity and arrhythmia.
The average duration of hospital treatment was 9 
days.
Discussion
Thrombolytic therapy is of proven benefit for se-
lected patients with ischemic stroke. Completion of 
Fig. 1. Patient distribution according to age and sex.
Fig. 2. National Institutes of Health Stroke Scale (NIHSS) 
score on admission in male and female patients.
Fig. 3. National Institutes of Health Stroke Scale (NIHSS) 
score at discharge in male and female patients.
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9 large phase III trials of intravenous thrombolytic 
therapy, which employed various agents, doses, and 
time windows, has provided a substantial database to 
guide clinical practice. However, a number of large 
multicenter randomized placebo controlled trials have 
shown an overall benefit for early treatment with rt-
PA, despite an increased risk of early hemorrhage10.
The pivotal National Institutes of Neurological 
Disorders and Stroke (NINDS) tissue plasminogen 
activator (tPA) trials were completed in 1995 and ran-
domized 624 subjects within 3 hours of stroke onset 
to receive 0.9 mg/kg of intravenous tPA or placebo. 
These two trials found that patients treated with tPA 
within 3 hours of onset had a substantially better 
chance of functional independence with minimal or no 
disability 3 months after treatment. The proportion of 
patients with minimal or no disability increased from 
38% with placebo to 50% with tPA, a 12% absolute 
improvement. The number needed to treat for 1 more 
patient to have a normal or near normal outcome was 
8, and the number needed to treat for 1 more patient 
to have an improved outcome was 3.111.
The favorable results of the NINDS tPA trials 
have generally been duplicated in phase IV studies ex-
amining the use of intravenous tPA in routine clinical 
practice. The largest study of actual clinical practice 
evaluated 6843 patients treated at 285 centers in 14 
countries and found the rate of complications and fa-
vorable outcomes similar to those of the NINDS tPA 
trials. These findings show that tPA is just as effective 
in clinical practice as in clinical trials when inclusion 
and exclusion guidelines are followed12.
The European Cooperative Acute Stroke Study 
(ECASS) I was completed in 1995 and randomized 
620 subjects within 6 hours of stroke onset to receive 
1.1 mg/kg of intravenous tPA or placebo. This study 
failed to find a benefit for the use of tPA within 6 
hours of stroke onset.
ECASS II was completed in 1998 and randomized 
800 subjects within 6 hours of stroke onset to receive 
0.9 mg/kg of intravenous tPA or placebo, and the out-
come in the tPA group was significantly better than in 
the placebo arm. 
Recently, pooled data from the six large random-
ized controlled trials (RCTs) of rt-PA involving 2775 
patients were analyzed to gain better insight into the 
effect of time to treatment on efficacy. The findings re-
ported recently confirm that the sooner the treatment 
is given to suitable stroke patients, the greater the 
benefit10. These results confirm the strong association 
between rapid treatment and favorable outcome13-15.
A Cochrane review of thrombolysis for acute isch-
emic stroke analyzed 18 RCTs of any thrombolytic 
agent8. The review included 5727 patients given uroki-
nase, streptokinase, recombinant pro-urokinase, or rt-
PA. About half of the data come from trials testing 
rt-PA. There is a paucity of data on patients aged >80 
years. Overall thrombolytic therapy, administered up 
to 6 hours after ischemic stroke, significantly reduced 
the proportion of patients who were dead or depen-
dent (modified Rankin, 3-6) at 3- to 6-month follow 
up. 
An independent reanalysis of the trials demon-
strated a robust treatment effect in favor of tPA. The 
use of tPA for acute ischemic stroke was approved by 
the US Food and Drug Administration (FDA) in 
1996 and subsequently by regulatory agencies in Can-
ada, Europe, South America, and Asia. rt-PA was li-
censed under the brand name Actilyse for use in acute 
ischemic stroke in April 2003 in the UK. It must be 
administered within a 3-hour time window and was 
launched under strict licensing guidelines. Under 
these, it can only be used by a physician specialist in 
acute stroke care and with experience in the use of 
thrombolytic treatments and appropriate facilities to 
monitor its use and complications13-15.
There have been a number of RCTs published 
from North America, Europe and Australia examin-
ing the role of thrombolysis in stroke. Many have used 
intravenous tPA but some have used intra-arterial in-
fusion, especially for vertebrobasilar strokes. These 
studies include:
MAST-E Multicentre Acute Stroke Trial-Europe
MAST-I Multicentre Acute Stroke Trial-Italy
ASK Australian Streptokinase
NINDS National Institute of Neurological Disorders 
and Stroke (USA)
ECASS European Cooperative Acute Stroke Study
ECASSS II European and Australian Cooperative 
Acute Stroke Study II
ATLANTIS Alteplase Thrombolysis for Acute Non-
interventional Treatment in Ischaemic Stroke
STAT Stroke Treatment with Ancrod Trial 
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Conclusion
The benefits of thrombolysis using rt-PA within 
three hours of stroke onset can be substantial. By pro-
moting rapid recognition of stroke symptoms in the 
community, prompt transport of patients to special-
ized acute stroke units for early investigation, neu-
roimaging, stabilization and treatment, there would 
be substantial net benefit for all patients with stroke 
and not just for the small proportion (currently be-
tween 2.5% and 5%) eligible for thrombolysis. Clearly, 
we have a long way to go before “brain attack” is given 
the same degree of priority and urgency as “heart at-
tack” currently is. The results are very encouraging, 
but complications from treatment can mean that the 
sooner tPA is given to patients, the greater the ben-
efit.
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Sažetak
NAŠA ISKUSTVA S TROMBOLITIČKOM TERAPIJOM – PRELIMINARNO IZVJEŠĆE
S. Miljković, T. Rabi-Žikić, M. Arbutina, Z. Vujković, D. Račić, S. Crnčević, A. Ješić i M. Žikić
Moždani udar je naglo nastali, akutni oblik fokalnog ili globalnog poremećaja moždane funkcije, koji traje duže od 
jednog sata, poremećaja koji nema drugog vidljivog uzroka osim vaskularnog. Predstavlja završnu fazu bolesti lokalizira-
ne na moždanim arterijama, glavni je uzrok onesposobljenosti i drugi uzrok smrtnog ishoda. U današnje vrijeme postoji 
mogućnost veoma uspješnog liječenja ishemijskog moždanog udara primjenom moćnog oružja, kauzalne trombolitičke 
terapije. Ovdje se daje preliminarni prikaz naših iskustava u primjeni trombolitičke terapije kod bolesnika s ishemijskim 
moždanim udarom. U radu se prikazuju rezultati liječenja 20 bolesnika koji su primili trombolitičku terapiju u prva tri 
sata od početnih simptoma moždanog udara, od kojih je 19 preživjelo, a jedan bolesnik je umro od sporednih učinaka 
terapije, tj. intracerebralnog krvarenja. Kod 17 bolesnika došlo je do potpunog oporavka bez neurološkog deficita, dok su 
dva bolesnika imala minimalnu onesposobljenost, Rankinov zbir 2, nakon tri mjeseca od događaja. Trombolitička terapija 
je i prema našim prvim iskustvima terapija izbora u liječenju ishemijskog moždanog udara, ako se primjenjuje strogo prema 
propisanim uputama. 
Ključne riječi: Moždani udar; Moždana ishemija; Trombolitička terapija
18. WAHLGREN N, AHMED N, DAVALOS A, FORD GA, 
GROND M, HACKE W, et al. Thrombolysis with alteplase 
for acute ischaemic stroke in the Safe Implementation of 
Thrombolysis in Stroke-Monitoring Study (SITS-MOST): 
an observational study. Lancet 2007;369(9558):275-82.

